title: Cannabinoid abuse and addiction: Clinical and preclinical findings.
abstract: Cannabinoid abuse disorders represent a widespread public health issue, but there are no approved medications for their treatment. This review describes efforts to understand the mechanisms of cannabinoid abuse and its adverse effects, to identify molecular targets for pharmacotherapy, and to evaluate potential treatments in human volunteers and animal models of cannabinoid reward, withdrawal, and relapse.
authors: Preclinical Pharmacology Section, Behavioral Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, NIH, DHHS, Baltimore, Maryland, USA.
authors: L V
authors: LV
authors: Panlilio
authors: Preclinical Pharmacology Section, Behavioral Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, NIH, DHHS, Baltimore, Maryland, USA.
authors: S R
authors: SR
authors: Goldberg
authors: Preclinical Pharmacology Section, Behavioral Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, NIH, DHHS, Baltimore, Maryland, USA.
authors: Z
authors: Z
authors: Justinova
mesh_terms: D058917:Adenosine A2 Receptor Antagonists / Q000627:therapeutic use; D000818:Animals; D002186:Cannabinoids / Q000009:adverse effects*; D004193:Discrimination Learning; D006801:Humans; D050601:Kynurenine 3-Monooxygenase / Q000037:antagonists & inhibitors; D002189:Marijuana Abuse / Q000188:drug therapy*; D012646:Self Administration; D013375:Substance Withdrawal Syndrome / Q000628:therapy; D019966:Substance-Related Disorders / Q000188:drug therapy*
chemical_list: D058917:Adenosine A2 Receptor Antagonists; D002186:Cannabinoids; D050601:Kynurenine 3-Monooxygenase